5 studies · 1 recommendation
Last updated: February 4, 2026
Two ACR clinical guidelines (2012, 2020) and three prospective cohort studies involving 444 gout patients establish tophi as critical markers warranting timely intervention. The 2020 ACR Guideline strongly recommends initiating urate-lowering therapy for all patients with tophaceous gout, targeting serum urate below 6 mg/dL to prevent progression and promote tophus resolution. Beyond joint damage, tophi independently predict metabolic complications: patients with tophi had a 2.6-fold increased risk of developing type 2 diabetes (OR=2.61; 95% CI: 1.50–4.54; p=0.001) over 2-8 years of follow-up. Among gout patients who developed diabetes, 59.3% had tophi versus 30.0% of those who remained diabetes-free. Visible or palpable tophi therefore warrant not only aggressive urate management but also screening for glucose dysregulation.
Authors: E. L. Nasonov, M. S. Eliseev, O. V. Zheliabina, S. I. Glukhova
Published: July 1, 2022
In this prospective cohort of 444 gout patients followed for a median of 5.66 years, the presence of tophi significantly increased the risk of developing type 2 diabetes (OR=2.61; 95% CI: 1.50–4.54; p=0.001). This 2.6-fold elevated risk was independent of other factors in multivariate analysis, suggesting tophi serve as a clinical marker for metabolic dysfunction beyond urate burden alone.
Authors: M. N. Chikina, M. S. Eliseev, O. V. Zhelyabina, S. I. Glukhova, T. S. Panevin, М. Н. Чикина, М. С. Елисеев, О. В. Желябина, С. И. Глухова, Т. С. Паневин
Published: February 19, 2022
In this prospective cohort study of 444 gout patients without diabetes at baseline, subcutaneous tophi presence was significantly associated with subsequent diabetes development. Among the 108 patients (24.3%) who developed type 2 diabetes over 2-8 years of follow-up, 59.3% had tophi compared to only 30.0% of those who remained diabetes-free (p=0.001). Logistic regression analysis confirmed tophi as an independent risk factor for diabetes development in gout patients.
Authors: M. N. Chikina, M. S. Eliseev, O. V. Zhelyabina, S. I. Glukhova, T. S. Panevin
Published: February 1, 2022
In a prospective study of 444 gout patients followed for 2-8 years, subcutaneous tophi were present in 59.3% of patients who developed type 2 diabetes compared to only 30.0% of those who did not develop diabetes (p=0.001). Logistic regression analysis confirmed that the presence of tophi independently increased the risk of type 2 diabetes development.
Authors: Abeles, Aryeh M., Bae, Sangmee Sharon, Brignardello‐petersen, Romina, Dalbeth, Nicola, Danve, Abhijeet, FitzGerald, John D., Gelber, Allan C., Guyatt, Gordon, Harrold, Leslie R., Khanna, Dinesh, Khanna, Puja P., Kim, Seoyoung C., King, Charles, Lenert, Aleksander, Levy, Gerald, Libbey, Caryn, Mikuls, Ted, Mount, David, Neogi, Tuhina, Pillinger, Michael H., Poon, Samuel, Qasim, Anila, Rosenthal, Ann, Sehra, Shiv T., Sharma, Tarun Sudhir Kumar, Sims, James Edward, Singh, Jasvinder A., Smith, Benjamin J., Toprover, Michael, Turgunbaev, Marat, Turner, Amy S., Wenger, Neil S., Zeng, Linan, Zhang, Mary Ann
Published: June 1, 2020
The 2020 ACR Guideline strongly recommends initiating urate-lowering therapy for all patients with tophaceous gout. Among 42 recommendations including 16 strong recommendations, the presence of tophi was identified as a key indication requiring treatment. The guideline emphasizes a treat-to-target strategy with serum urate goal below 6 mg/dL to prevent tophus progression and promote resolution of existing deposits.
Authors: Arellano, Becker, Becker, Becker, Bhole, Brook, Brook, Chao, Choi, Choi, Choi, Choi, Choi, Choi, Dalbeth, Dalbeth, Dalbeth, Dalbeth, Desai, Dessein, Grossman, Hande, Hande, Harrold, Hung, Hunt, Jordan, Jung, Khanna, Khanna, Krishnan, Krishnan, Lee, Lonjou, Lupton, McAdams DeMarco, Neogi, Neogi, Ottaviani, Perez-Ruiz, Perez-Ruiz, Perez-Ruiz, Pillinger, Pineda, Rees, Reinders, Reinders, Reinders, Roddy, Romeijnders, Schumacher, Shekelle, Singh, Singh, Singh, Somkrua, Stamp, Stamp, Stevenson, Sundy, Takahashi, Tassaneeyakul, Terkeltaub, Thiele, Thompson, Tsai, Yamanaka, Zhang, Zhang, Zhang, Zhang, Zhu, Zineh
Published: October 1, 2012
The ACR guideline identifies tophi as a pathognomonic feature of gout, found in articular, periarticular, bursal, bone, auricular, and cutaneous tissues. The guideline specifically addresses chronic gouty arthritis with tophaceous disease (termed chronic tophaceous gouty arthropathy) as requiring distinct management approaches. Tophi are detectable by physical examination or imaging and indicate long-term morbidity and impairment of health-related quality of life, particularly in patients with multiple comorbidities.
View Source →